Bristol-Myers Squibb Company (BMY) 10-Year Financial Performance & Capital Metrics

BMY • • Industrial / General

HealthcareLarge PharmaBroad-Based Pharmaceutical GiantsOncology-Focused Innovators

AboutBristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.Show more

Revenue $48.3B +7.3%
EBITDA $19.26B +5.6%
Net Income -$8.95B -211.5%
EPS (Diluted) -4.41 -214.2%
Gross Margin 56.79% +0.8%
EBITDA Margin 39.87% -1.6%
Operating Margin 20% +6.2%
Net Margin -18.53% -203.9%
ROE -39.01% -247.3%
ROIC 12.41% +19.3%
Debt/Equity 3.12 +122.2%
Interest Coverage 4.96 -31.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 28.9% free cash flow margin
✓Strong 5Y sales CAGR of 13.1%
✓Healthy dividend yield of 4.2%
✓Share count reduced 2.5% through buybacks

✗Weaknesses

✗High debt to equity ratio of 3.1x
✗Weak 3Y average ROE of 2.1%
✗Thin 5Y average net margin of 1.4%

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y11.77%

5Y13.06%

3Y1.36%

TTM1.26%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM183.2%

EPS CAGR

10Y-

5Y-

3Y-

TTM182.32%

ROCE

10Y Avg14.57%

5Y Avg10.2%

3Y Avg12.17%

Latest13.63%

Peer Comparison

Oncology-Focused Innovators

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
GILDGilead Sciences, Inc.	150.44B	121.26	319.11	6.04%	27.88%	37.8%	6.85%	1.39
AMGNAmgen Inc.	177.71B	330.03	43.65	18.57%	19.48%	72.82%	5.85%	10.23
CELG-RIBristol-Myers Squibb Company Ce		0.16	-0.04	7.32%	12.57%	32.47%		3.12
BMYBristol-Myers Squibb Company	115.26B	56.62	-12.84	7.32%	12.57%	32.47%	12.1%	3.12

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	16.56B	19.43B	20.78B	22.56B	26.14B	42.52B	46.38B	46.16B	45.01B	48.3B
Revenue Growth %	0.04%	0.17%	0.07%	0.09%	0.16%	0.63%	0.09%	-0%	-0.02%	0.07%
Cost of Goods Sold+	3.75B	4.93B	5.82B	6.49B	8.89B	20.82B	19.62B	19.67B	19.65B	20.87B
COGS % of Revenue	0.23%	0.25%	0.28%	0.29%	0.34%	0.49%	0.42%	0.43%	0.44%	0.43%
Gross Profit+	12.81B	14.49B	14.96B	16.07B	17.25B	21.7B	26.76B	26.49B	25.36B	27.43B
Gross Margin %	0.77%	0.75%	0.72%	0.71%	0.66%	0.51%	0.58%	0.57%	0.56%	0.57%
Gross Profit Growth %	0.07%	0.13%	0.03%	0.07%	0.07%	0.26%	0.23%	-0.01%	-0.04%	0.08%
Operating Expenses+	8.87B	9.32B	9.72B	9.68B	10.81B	17.21B	17.22B	17.22B	16.89B	17.77B
OpEx % of Revenue	0.54%	0.48%	0.47%	0.43%	0.41%	0.4%	0.37%	0.37%	0.38%	0.37%
Selling, General & Admin	4.83B	4.91B	4.75B	4.55B	4.86B	7.65B	7.69B	7.81B	7.68B	7.87B
SG&A % of Revenue	0.29%	0.25%	0.23%	0.2%	0.19%	0.18%	0.17%	0.17%	0.17%	0.16%
Research & Development	4.04B	4.41B	4.97B	5.13B	5.95B	9.56B	9.53B	9.41B	9.21B	9.78B
R&D % of Revenue	0.24%	0.23%	0.24%	0.23%	0.23%	0.22%	0.21%	0.2%	0.2%	0.2%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	127M
Operating Income+	3.94B	5.18B	5.24B	6.39B	6.44B	4.49B	9.54B	9.27B	8.47B	9.66B
Operating Margin %	0.24%	0.27%	0.25%	0.28%	0.25%	0.11%	0.21%	0.2%	0.19%	0.2%
Operating Income Growth %	0.26%	0.32%	0.01%	0.22%	0.01%	-0.3%	1.12%	-0.03%	-0.09%	0.14%
EBITDA+	4.31B	5.56B	6.03B	7.03B	8.19B	14.87B	20.23B	19.55B	18.23B	19.26B
EBITDA Margin %	0.26%	0.29%	0.29%	0.31%	0.31%	0.35%	0.44%	0.42%	0.41%	0.4%
EBITDA Growth %	0.2%	0.29%	0.08%	0.17%	0.16%	0.82%	0.36%	-0.03%	-0.07%	0.06%
D&A (Non-Cash Add-back)	376M	382M	789M	637M	1.75B	10.38B	10.69B	10.28B	9.76B	9.6B
EBIT	2.26B	6.08B	5.33B	6.15B	5.63B	-5.45B	9.43B	8.95B	9.61B	-6.43B
Net Interest Income+	-184M	-167M	-196M	-183M	-656M	-1.42B	-1.33B	-1.23B	-1.17B	-1.95B
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	184M	167M	196M	183M	656M	1.42B	1.33B	1.23B	1.17B	1.95B
Other Income/Expense	-1.86B	736M	-108M	-426M	-1.46B	-11.36B	-1.44B	-1.56B	-32M	-18.04B
Pretax Income+	2.08B	5.92B	5.13B	5.97B	4.97B	-6.87B	8.1B	7.71B	8.44B	-8.38B
Pretax Margin %	0.13%	0.3%	0.25%	0.26%	0.19%	-0.16%	0.17%	0.17%	0.19%	-0.17%
Income Tax+	446M	1.41B	4.16B	1.02B	1.51B	2.12B	1.08B	1.37B	400M	554M
Effective Tax Rate %	0.75%	0.75%	0.2%	0.82%	0.69%	1.31%	0.86%	0.82%	0.95%	1.07%
Net Income+	1.56B	4.46B	1.01B	4.92B	3.44B	-8.99B	6.99B	6.33B	8.03B	-8.95B
Net Margin %	0.09%	0.23%	0.05%	0.22%	0.13%	-0.21%	0.15%	0.14%	0.18%	-0.19%
Net Income Growth %	-0.22%	1.85%	-0.77%	3.89%	-0.3%	-3.62%	1.78%	-0.1%	0.27%	-2.12%
Net Income (Continuing)	1.63B	4.51B	975M	4.95B	3.46B	-8.99B	7.01B	6.34B	8.04B	-8.93B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	158M	170M	106M	96M	100M	60M	60M	57M	55M	53M
EPS (Diluted)+	0.97	2.65	0.61	3.03	2.01	-3.98	3.12	2.95	3.86	-4.41
EPS Growth %	-0.19%	1.73%	-0.77%	3.97%	-0.34%	-2.98%	1.78%	-0.05%	0.31%	-2.14%
EPS (Basic)	0.97	2.67	0.61	3.03	2.02	-3.98	3.15	2.97	3.88	-4.41
Diluted Shares Outstanding	1.68B	1.68B	1.65B	1.64B	1.71B	2.26B	2.25B	2.15B	2.08B	2.03B
Basic Shares Outstanding	1.67B	1.67B	1.65B	1.63B	1.71B	2.26B	2.22B	2.13B	2.07B	2.03B
Dividend Payout Ratio	1.58%	0.57%	2.56%	0.53%	0.78%	-	0.63%	0.73%	0.59%	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.41B	13.7B	14.85B	17.72B	29.35B	30.19B	33.26B	27.27B	31.77B	29.78B
Cash & Short-Term Investments	4.27B	6.35B	6.81B	8.76B	15.39B	16.45B	17.22B	9.25B	12.28B	10.86B
Cash Only	2.38B	4.24B	5.42B	6.91B	12.35B	14.55B	13.98B	9.12B	11.46B	10.35B
Short-Term Investments	1.89B	2.11B	1.39B	1.85B	3.05B	1.9B	3.24B	130M	816M	513M
Accounts Receivable	4.3B	5.54B	6.3B	5.75B	7.68B	10.55B	12.52B	13.94B	15.26B	14.42B
Days Sales Outstanding	94.75	104.14	110.68	92.98	107.29	90.6	98.49	110.21	123.79	109
Inventory	1.22B	1.24B	1.17B	1.2B	4.29B	2.07B	2.1B	2.34B	2.66B	2.56B
Days Inventory Outstanding	118.72	91.84	73.15	67.25	176.16	36.36	38.97	43.41	49.45	44.72
Other Current Assets	0	0	0	899M	1.23B	-685M	1.43B	1.74B	1.56B	1.94B
Total Non-Current Assets+	21.33B	20B	18.7B	17.27B	100.59B	88.29B	76.05B	69.55B	63.39B	62.82B
Property, Plant & Equipment	4.41B	4.98B	5B	5.03B	6.96B	6.75B	6.97B	7.47B	8.04B	8.36B
Fixed Asset Turnover	3.75x	3.90x	4.15x	4.49x	3.76x	6.30x	6.66x	6.18x	5.60x	5.78x
Goodwill	6.88B	6.88B	6.86B	6.54B	22.49B	20.55B	20.5B	21.15B	21.17B	21.72B
Intangible Assets	1.42B	1.39B	1.21B	1.09B	63.97B	53.45B	42.77B	36.35B	27.48B	23.64B
Long-Term Investments	4.66B	2.72B	2.48B	1.77B	4.17B	4.51B	2.71B	2.19B	2.5B	2.51B
Other Non-Current Assets	1.12B	1.05B	1.53B	2.02B	2.5B	1.88B	1.66B	1.04B	1.43B	2.36B
Total Assets+	31.75B	33.71B	33.55B	34.99B	129.94B	118.48B	109.31B	96.82B	95.16B	92.6B
Asset Turnover	0.52x	0.58x	0.62x	0.64x	0.20x	0.36x	0.42x	0.48x	0.47x	0.52x
Asset Growth %	-0.06%	0.06%	-0%	0.04%	2.71%	-0.09%	-0.08%	-0.11%	-0.02%	-0.03%
Total Current Liabilities+	8.02B	8.84B	9.56B	10.65B	18.3B	19.08B	21.87B	21.89B	22.26B	23.77B
Accounts Payable	1.56B	1.66B	2.25B	1.89B	2.44B	2.71B	2.95B	3.04B	3.26B	3.6B
Days Payables Outstanding	152.16	123.15	141.03	106.47	100.33	47.57	54.85	56.41	60.54	63
Short-Term Debt	139M	992M	987M	1.7B	3.35B	2.34B	4.95B	4.26B	3.12B	2.05B
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	951M	862M	909M	5.75B	9.35B	11.65B	11.48B	11.99B	12.79B	14.6B
Current Ratio	1.30x	1.55x	1.55x	1.66x	1.60x	1.58x	1.52x	1.25x	1.43x	1.25x
Quick Ratio	1.15x	1.41x	1.43x	1.55x	1.37x	1.47x	1.43x	1.14x	1.31x	1.15x
Cash Conversion Cycle	61.31	72.84	42.8	53.75	183.12	79.4	82.6	97.2	112.7	90.72
Total Non-Current Liabilities+	9.31B	8.52B	12.14B	10.21B	59.94B	61.52B	51.44B	43.81B	43.41B	52.44B
Long-Term Debt	6.55B	5.72B	6.97B	5.65B	43.39B	48.34B	39.6B	35.06B	36.65B	47.6B
Capital Lease Obligations	0	0	0	0	672M	833M	874M	1.26B	1.53B	1.37B
Deferred Tax Liabilities	0	0	0	19M	6.45B	5.41B	4.5B	2.17B	338M	369M
Other Non-Current Liabilities	2.17B	2.26B	4.71B	4.07B	9.01B	6.59B	6.13B	5.05B	4.59B	2.87B
Total Liabilities	17.32B	17.36B	21.7B	20.86B	78.25B	80.6B	73.31B	65.7B	65.67B	76.22B
Total Debt+	6.69B	6.71B	7.96B	7.35B	47.54B	51.67B	45.6B	40.72B	41.46B	51.2B
Net Debt	4.3B	2.47B	2.54B	438M	35.19B	37.13B	31.62B	31.59B	30B	40.85B
Debt / Equity	0.46x	0.41x	0.67x	0.52x	0.92x	1.36x	1.27x	1.31x	1.41x	3.12x
Debt / EBITDA	1.55x	1.21x	1.32x	1.05x	5.81x	3.47x	2.25x	2.08x	2.27x	2.66x
Net Debt / EBITDA	1.00x	0.44x	0.42x	0.06x	4.30x	2.50x	1.56x	1.62x	1.65x	2.12x
Interest Coverage	21.40x	31.01x	26.73x	34.94x	9.82x	3.16x	7.15x	7.53x	7.27x	4.96x
Total Equity+	14.42B	16.35B	11.85B	14.13B	51.7B	37.88B	36.01B	31.12B	29.48B	16.39B
Equity Growth %	-0.04%	0.13%	-0.28%	0.19%	2.66%	-0.27%	-0.05%	-0.14%	-0.05%	-0.44%
Book Value per Share	8.59	9.73	7.17	8.63	30.20	16.78	16.04	14.50	14.19	8.08
Total Shareholders' Equity	14.27B	16.18B	11.74B	14.03B	51.6B	37.82B	35.95B	31.06B	29.43B	16.34B
Common Stock	221M	221M	221M	221M	292M	292M	292M	292M	292M	292M
Retained Earnings	31.61B	33.51B	31.16B	34.06B	34.47B	21.28B	23.82B	25.5B	28.77B	14.91B
Treasury Stock	-16.56B	-16.78B	-19.25B	-19.57B	-25.36B	-26.24B	-31.26B	-38.62B	-43.77B	-43.66B
Accumulated OCI	-2.47B	-2.5B	-2.29B	-2.76B	-1.52B	-1.84B	-1.27B	-1.28B	-1.55B	-1.24B
Minority Interest	158M	170M	106M	96M	100M	60M	60M	57M	55M	53M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	2.1B	3.06B	5.28B	7.07B	8.21B	14.05B	16.21B	13.07B	13.86B	15.19B
Operating CF Margin %	0.13%	0.16%	0.25%	0.31%	0.31%	0.33%	0.35%	0.28%	0.31%	0.31%
Operating CF Growth %	-0.33%	0.45%	0.72%	0.34%	0.16%	0.71%	0.15%	-0.19%	0.06%	0.1%
Net Income	1.63B	4.51B	975M	4.95B	3.46B	-8.99B	7.01B	6.34B	8.04B	-8.93B
Depreciation & Amortization	376M	382M	789M	637M	1.75B	10.38B	10.69B	10.28B	9.76B	9.6B
Stock-Based Compensation	235M	205M	199M	221M	441M	779M	583M	457M	518M	507M
Deferred Taxes	-347M	-204M	453M	45M	-924M	983M	-1.39B	-2.74B	-3.29B	-2.09B
Other Non-Cash Items	945M	-680M	714M	999M	317M	9.92B	578M	955M	744M	15.29B
Working Capital Changes	-735M	-1.15B	2.15B	217M	3.17B	983M	-1.26B	-2.23B	-1.91B	810M
Change in Receivables	-942M	-803M	-431M	-429M	752M	-646M	-1.05B	-663M	-995M	264M
Change in Inventory	97M	-152M	-29M	-216M	463M	2.67B	13M	-69M	-751M	-486M
Change in Payables	-919M	104M	320M	-59M	229M	188M	245M	109M	198M	184M
Cash from Investing+	-1.57B	1.48B	-66M	-2B	-9.91B	-10.86B	-538M	-1.06B	-2.29B	-21.35B
Capital Expenditures	-820M	-1.22B	-1.05B	-951M	-836M	-753M	-973M	-1.12B	-1.21B	-1.25B
CapEx % of Revenue	0.05%	0.06%	0.05%	0.04%	0.03%	0.02%	0.02%	0.02%	0.03%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	-3.62B	-2.65B	-4.08B	-3.54B	7.62B	-1.15B	-16.22B	-16.96B	-9.42B	5.13B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-2.48B	-2.55B	-2.58B	-2.61B	-2.68B	-4.08B	-4.4B	-4.63B	-4.74B	-4.86B
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-9M	15M	-22M	-54M	-53M	542M	641M	984M	27M	-106M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	1.28B	1.84B	4.22B	6.12B	7.37B	13.3B	15.23B	11.95B	12.65B	13.94B
FCF Margin %	0.08%	0.09%	0.2%	0.27%	0.28%	0.31%	0.33%	0.26%	0.28%	0.29%
FCF Growth %	-0.51%	0.43%	1.29%	0.45%	0.21%	0.8%	0.15%	-0.22%	0.06%	0.1%
FCF per Share	0.77	1.10	2.55	3.74	4.31	5.89	6.79	5.57	6.09	6.88
FCF Conversion (FCF/Net Income)	1.35x	0.69x	5.24x	1.44x	2.39x	-1.56x	2.32x	2.07x	1.73x	-1.70x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	10.64%	28.97%	7.14%	37.88%	10.45%	-20.08%	18.93%	18.85%	26.48%	-39.01%
Return on Invested Capital (ROIC)	16.42%	20.69%	23.67%	33.13%	9.52%	4.16%	10.03%	10.67%	10.4%	12.41%
Gross Margin	77.33%	74.61%	72%	71.25%	65.98%	51.04%	57.69%	57.39%	56.34%	56.79%
Net Margin	9.45%	22.94%	4.85%	21.81%	13.15%	-21.16%	15.08%	13.71%	17.83%	-18.53%
Debt / Equity	0.46x	0.41x	0.67x	0.52x	0.92x	1.36x	1.27x	1.31x	1.41x	3.12x
Interest Coverage	21.40x	31.01x	26.73x	34.94x	9.82x	3.16x	7.15x	7.53x	7.27x	4.96x
FCF Conversion	1.35x	0.69x	5.24x	1.44x	2.39x	-1.56x	2.32x	2.07x	1.73x	-1.70x
Revenue Growth	4.29%	17.31%	6.94%	8.59%	15.89%	62.62%	9.1%	-0.49%	-2.5%	7.32%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Eliquis	1.86B	3.34B	4.87B	6.44B	7.93B	9.17B	10.76B	11.79B	12.21B	13.33B
Eliquis Growth	-	79.73%	45.74%	32.14%	23.16%	15.63%	17.39%	9.54%	3.54%	9.23%
Opdivo	942M	3.77B	4.95B	6.74B	7.2B	6.99B	7.52B	8.25B	9.01B	9.3B
Opdivo Growth	-	300.64%	31.11%	36.12%	6.96%	-2.94%	7.59%	9.65%	9.21%	3.27%
Revlimid	-	-	-	-	1.3B	12.11B	12.82B	9.98B	6.1B	5.77B
Revlimid Growth	-	-	-	-	-	831.95%	5.91%	-22.17%	-38.90%	-5.31%
Orencia	1.89B	2.27B	2.48B	2.71B	2.98B	3.16B	3.31B	3.46B	3.6B	3.68B
Orencia Growth	-	20.16%	9.45%	9.32%	9.85%	6.05%	4.72%	4.78%	3.95%	2.25%
Pomalyst/Imnovid	-	-	-	-	322M	3.07B	3.33B	3.5B	3.44B	3.54B
Pomalyst/Imnovid Growth	-	-	-	-	-	853.42%	8.53%	4.95%	-1.60%	3.02%
Yervoy	1.13B	1.05B	1.24B	1.33B	1.49B	1.68B	2.03B	2.13B	2.24B	2.53B
Yervoy Growth	-	-6.48%	18.14%	6.91%	11.95%	12.96%	20.45%	5.18%	5.02%	13.05%
Reblozyl	-	-	-	-	-	274M	551M	717M	1.01B	1.77B
Reblozyl Growth	-	-	-	-	-	-	101.09%	30.13%	40.59%	75.89%
Other Growth Brands	-	-	-	-	-	-	-	-	-	1.6B
Other Growth Brands Growth	-	-	-	-	-	-	-	-	-	-
Sprycel	1.62B	1.82B	2B	2B	2.11B	2.14B	2.12B	2.17B	1.93B	1.29B
Sprycel Growth	-	12.59%	9.92%	-0.25%	5.50%	1.42%	-1.07%	2.27%	-10.85%	-33.37%
Opdualag	-	-	-	-	-	-	-	252M	627M	928M
Opdualag Growth	-	-	-	-	-	-	-	-	148.81%	48.01%
Other Legacy Brands	-	-	-	-	-	-	-	-	-	925M
Other Legacy Brands Growth	-	-	-	-	-	-	-	-	-	-
Abraxane	-	-	-	-	166M	1.25B	1.18B	811M	1B	875M
Abraxane Growth	-	-	-	-	-	651.20%	-5.29%	-31.33%	23.80%	-12.85%
Breyanzi	-	-	-	-	-	-	87M	182M	364M	747M
Breyanzi Growth	-	-	-	-	-	-	-	109.20%	100.00%	105.22%
Camzyos	-	-	-	-	-	-	-	24M	231M	602M
Camzyos Growth	-	-	-	-	-	-	-	-	862.50%	160.61%
Zeposia	-	-	-	-	-	12M	134M	250M	434M	566M
Zeposia Growth	-	-	-	-	-	-	1016.67%	86.57%	73.60%	30.41%
Abecma	-	-	-	-	-	-	164M	388M	472M	406M
Abecma Growth	-	-	-	-	-	-	-	136.59%	21.65%	-13.98%
Sotyktu	-	-	-	-	-	-	-	8M	170M	246M
Sotyktu Growth	-	-	-	-	-	-	-	-	2025.00%	44.71%
Krazati	-	-	-	-	-	-	-	-	-	126M
Krazati Growth	-	-	-	-	-	-	-	-	-	-
Cobenfy	-	-	-	-	-	-	-	-	-	10M
Cobenfy Growth	-	-	-	-	-	-	-	-	-	-
Mature Products And All Other	2.57B	2.14B	2.11B	1.63B	1.67B	1.31B	1.9B	1.75B	-	-
Mature Products And All Other Growth	-	-16.65%	-1.45%	-22.82%	2.70%	-21.45%	44.49%	-7.95%	-	-
Baraclude	1.31B	1.19B	1.05B	744M	555M	447M	-	-	-	-
Baraclude Growth	-	-9.15%	-11.74%	-29.28%	-25.40%	-19.46%	-	-	-	-
Empliciti	3M	150M	231M	247M	357M	381M	-	-	-	-
Empliciti Growth	-	4900.00%	54.00%	6.93%	44.53%	6.72%	-	-	-	-
Reyataz	1.14B	912M	698M	427M	-	-	-	-	-	-
Reyataz Growth	-	-19.93%	-23.46%	-38.83%	-	-	-	-	-	-
Sustiva Franchise	1.25B	1.06B	729M	283M	-	-	-	-	-	-
Sustiva Franchise Growth	-	-14.94%	-31.55%	-61.18%	-	-	-	-	-	-
Hepatitis C Portfolio	1.6B	1.58B	406M	17M	-	-	-	-	-	-
Hepatitis C Portfolio Growth	-	-1.56%	-74.27%	-95.81%	-	-	-	-	-	-
Abilify	746M	128M	-	-	-	-	-	-	-	-
Abilify Growth	-	-82.84%	-	-	-	-	-	-	-	-
Erbitux	501M	-	-	-	-	-	-	-	-	-
Erbitux Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	8.19B	10.72B	11.36B	12.59B	15.34B	26.58B	29.21B	31.83B	31.55B	34.1B
UNITED STATES Growth	-	30.92%	5.95%	10.81%	21.90%	73.23%	9.92%	8.95%	-0.86%	8.08%
Rest Of World	4.14B	3.96B	3.88B	3.73B	4.01B	5.46B	5.63B	-	12.75B	13.2B
Rest Of World Growth	-	-4.30%	-2.19%	-3.71%	7.50%	35.98%	3.21%	-	-	3.51%
Other Region	739M	528M	553M	584M	524M	631M	852M	834M	699M	996M
Other Region Growth	-	-28.55%	4.73%	5.61%	-10.27%	20.42%	35.02%	-2.11%	-16.19%	42.49%
Europe	3.49B	4.21B	4.99B	5.66B	6.27B	9.85B	10.69B	13.5B	-	-
Europe Growth	-	20.74%	18.34%	13.43%	10.75%	57.25%	8.46%	26.29%	-	-

Frequently Asked Questions

Growth & Financials

Bristol-Myers Squibb Company (BMY) reported $48.03B in revenue for fiscal year 2024. This represents a 126% increase from $21.24B in 2011.

Bristol-Myers Squibb Company (BMY) grew revenue by 7.3% over the past year. This is steady growth.

Yes, Bristol-Myers Squibb Company (BMY) is profitable, generating $6.04B in net income for fiscal year 2024 (-18.5% net margin).

Dividend & Returns

Yes, Bristol-Myers Squibb Company (BMY) pays a dividend with a yield of 4.24%. This makes it attractive for income-focused investors.

Bristol-Myers Squibb Company (BMY) has a return on equity (ROE) of -39.0%. Negative ROE indicates the company is unprofitable.

Bristol-Myers Squibb Company (BMY) generated $15.30B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Bristol-Myers Squibb Company (BMY) 10-Year Financial Performance & Capital Metrics

BMY • • Industrial / General

HealthcareLarge PharmaBroad-Based Pharmaceutical GiantsOncology-Focused Innovators

Revenue $48.3B +7.3%
EBITDA $19.26B +5.6%
Net Income -$8.95B -211.5%
EPS (Diluted) -4.41 -214.2%
Gross Margin 56.79% +0.8%
EBITDA Margin 39.87% -1.6%
Operating Margin 20% +6.2%
Net Margin -18.53% -203.9%
ROE -39.01% -247.3%
ROIC 12.41% +19.3%
Debt/Equity 3.12 +122.2%
Interest Coverage 4.96 -31.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 28.9% free cash flow margin
✓Strong 5Y sales CAGR of 13.1%
✓Healthy dividend yield of 4.2%
✓Share count reduced 2.5% through buybacks

✗Weaknesses

✗High debt to equity ratio of 3.1x
✗Weak 3Y average ROE of 2.1%
✗Thin 5Y average net margin of 1.4%

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y11.77%

5Y13.06%

3Y1.36%

TTM1.26%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM183.2%

EPS CAGR

10Y-

5Y-

3Y-

TTM182.32%

ROCE

10Y Avg14.57%

5Y Avg10.2%

3Y Avg12.17%

Latest13.63%

Peer Comparison

Oncology-Focused Innovators

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
GILDGilead Sciences, Inc.	150.44B	121.26	319.11	6.04%	27.88%	37.8%	6.85%	1.39
AMGNAmgen Inc.	177.71B	330.03	43.65	18.57%	19.48%	72.82%	5.85%	10.23
CELG-RIBristol-Myers Squibb Company Ce		0.16	-0.04	7.32%	12.57%	32.47%		3.12
BMYBristol-Myers Squibb Company	115.26B	56.62	-12.84	7.32%	12.57%	32.47%	12.1%	3.12

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	16.56B	19.43B	20.78B	22.56B	26.14B	42.52B	46.38B	46.16B	45.01B	48.3B
Revenue Growth %	0.04%	0.17%	0.07%	0.09%	0.16%	0.63%	0.09%	-0%	-0.02%	0.07%
Cost of Goods Sold+	3.75B	4.93B	5.82B	6.49B	8.89B	20.82B	19.62B	19.67B	19.65B	20.87B
COGS % of Revenue	0.23%	0.25%	0.28%	0.29%	0.34%	0.49%	0.42%	0.43%	0.44%	0.43%
Gross Profit+	12.81B	14.49B	14.96B	16.07B	17.25B	21.7B	26.76B	26.49B	25.36B	27.43B
Gross Margin %	0.77%	0.75%	0.72%	0.71%	0.66%	0.51%	0.58%	0.57%	0.56%	0.57%
Gross Profit Growth %	0.07%	0.13%	0.03%	0.07%	0.07%	0.26%	0.23%	-0.01%	-0.04%	0.08%
Operating Expenses+	8.87B	9.32B	9.72B	9.68B	10.81B	17.21B	17.22B	17.22B	16.89B	17.77B
OpEx % of Revenue	0.54%	0.48%	0.47%	0.43%	0.41%	0.4%	0.37%	0.37%	0.38%	0.37%
Selling, General & Admin	4.83B	4.91B	4.75B	4.55B	4.86B	7.65B	7.69B	7.81B	7.68B	7.87B
SG&A % of Revenue	0.29%	0.25%	0.23%	0.2%	0.19%	0.18%	0.17%	0.17%	0.17%	0.16%
Research & Development	4.04B	4.41B	4.97B	5.13B	5.95B	9.56B	9.53B	9.41B	9.21B	9.78B
R&D % of Revenue	0.24%	0.23%	0.24%	0.23%	0.23%	0.22%	0.21%	0.2%	0.2%	0.2%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	127M
Operating Income+	3.94B	5.18B	5.24B	6.39B	6.44B	4.49B	9.54B	9.27B	8.47B	9.66B
Operating Margin %	0.24%	0.27%	0.25%	0.28%	0.25%	0.11%	0.21%	0.2%	0.19%	0.2%
Operating Income Growth %	0.26%	0.32%	0.01%	0.22%	0.01%	-0.3%	1.12%	-0.03%	-0.09%	0.14%
EBITDA+	4.31B	5.56B	6.03B	7.03B	8.19B	14.87B	20.23B	19.55B	18.23B	19.26B
EBITDA Margin %	0.26%	0.29%	0.29%	0.31%	0.31%	0.35%	0.44%	0.42%	0.41%	0.4%
EBITDA Growth %	0.2%	0.29%	0.08%	0.17%	0.16%	0.82%	0.36%	-0.03%	-0.07%	0.06%
D&A (Non-Cash Add-back)	376M	382M	789M	637M	1.75B	10.38B	10.69B	10.28B	9.76B	9.6B
EBIT	2.26B	6.08B	5.33B	6.15B	5.63B	-5.45B	9.43B	8.95B	9.61B	-6.43B
Net Interest Income+	-184M	-167M	-196M	-183M	-656M	-1.42B	-1.33B	-1.23B	-1.17B	-1.95B
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	184M	167M	196M	183M	656M	1.42B	1.33B	1.23B	1.17B	1.95B
Other Income/Expense	-1.86B	736M	-108M	-426M	-1.46B	-11.36B	-1.44B	-1.56B	-32M	-18.04B
Pretax Income+	2.08B	5.92B	5.13B	5.97B	4.97B	-6.87B	8.1B	7.71B	8.44B	-8.38B
Pretax Margin %	0.13%	0.3%	0.25%	0.26%	0.19%	-0.16%	0.17%	0.17%	0.19%	-0.17%
Income Tax+	446M	1.41B	4.16B	1.02B	1.51B	2.12B	1.08B	1.37B	400M	554M
Effective Tax Rate %	0.75%	0.75%	0.2%	0.82%	0.69%	1.31%	0.86%	0.82%	0.95%	1.07%
Net Income+	1.56B	4.46B	1.01B	4.92B	3.44B	-8.99B	6.99B	6.33B	8.03B	-8.95B
Net Margin %	0.09%	0.23%	0.05%	0.22%	0.13%	-0.21%	0.15%	0.14%	0.18%	-0.19%
Net Income Growth %	-0.22%	1.85%	-0.77%	3.89%	-0.3%	-3.62%	1.78%	-0.1%	0.27%	-2.12%
Net Income (Continuing)	1.63B	4.51B	975M	4.95B	3.46B	-8.99B	7.01B	6.34B	8.04B	-8.93B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	158M	170M	106M	96M	100M	60M	60M	57M	55M	53M
EPS (Diluted)+	0.97	2.65	0.61	3.03	2.01	-3.98	3.12	2.95	3.86	-4.41
EPS Growth %	-0.19%	1.73%	-0.77%	3.97%	-0.34%	-2.98%	1.78%	-0.05%	0.31%	-2.14%
EPS (Basic)	0.97	2.67	0.61	3.03	2.02	-3.98	3.15	2.97	3.88	-4.41
Diluted Shares Outstanding	1.68B	1.68B	1.65B	1.64B	1.71B	2.26B	2.25B	2.15B	2.08B	2.03B
Basic Shares Outstanding	1.67B	1.67B	1.65B	1.63B	1.71B	2.26B	2.22B	2.13B	2.07B	2.03B
Dividend Payout Ratio	1.58%	0.57%	2.56%	0.53%	0.78%	-	0.63%	0.73%	0.59%	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.41B	13.7B	14.85B	17.72B	29.35B	30.19B	33.26B	27.27B	31.77B	29.78B
Cash & Short-Term Investments	4.27B	6.35B	6.81B	8.76B	15.39B	16.45B	17.22B	9.25B	12.28B	10.86B
Cash Only	2.38B	4.24B	5.42B	6.91B	12.35B	14.55B	13.98B	9.12B	11.46B	10.35B
Short-Term Investments	1.89B	2.11B	1.39B	1.85B	3.05B	1.9B	3.24B	130M	816M	513M
Accounts Receivable	4.3B	5.54B	6.3B	5.75B	7.68B	10.55B	12.52B	13.94B	15.26B	14.42B
Days Sales Outstanding	94.75	104.14	110.68	92.98	107.29	90.6	98.49	110.21	123.79	109
Inventory	1.22B	1.24B	1.17B	1.2B	4.29B	2.07B	2.1B	2.34B	2.66B	2.56B
Days Inventory Outstanding	118.72	91.84	73.15	67.25	176.16	36.36	38.97	43.41	49.45	44.72
Other Current Assets	0	0	0	899M	1.23B	-685M	1.43B	1.74B	1.56B	1.94B
Total Non-Current Assets+	21.33B	20B	18.7B	17.27B	100.59B	88.29B	76.05B	69.55B	63.39B	62.82B
Property, Plant & Equipment	4.41B	4.98B	5B	5.03B	6.96B	6.75B	6.97B	7.47B	8.04B	8.36B
Fixed Asset Turnover	3.75x	3.90x	4.15x	4.49x	3.76x	6.30x	6.66x	6.18x	5.60x	5.78x
Goodwill	6.88B	6.88B	6.86B	6.54B	22.49B	20.55B	20.5B	21.15B	21.17B	21.72B
Intangible Assets	1.42B	1.39B	1.21B	1.09B	63.97B	53.45B	42.77B	36.35B	27.48B	23.64B
Long-Term Investments	4.66B	2.72B	2.48B	1.77B	4.17B	4.51B	2.71B	2.19B	2.5B	2.51B
Other Non-Current Assets	1.12B	1.05B	1.53B	2.02B	2.5B	1.88B	1.66B	1.04B	1.43B	2.36B
Total Assets+	31.75B	33.71B	33.55B	34.99B	129.94B	118.48B	109.31B	96.82B	95.16B	92.6B
Asset Turnover	0.52x	0.58x	0.62x	0.64x	0.20x	0.36x	0.42x	0.48x	0.47x	0.52x
Asset Growth %	-0.06%	0.06%	-0%	0.04%	2.71%	-0.09%	-0.08%	-0.11%	-0.02%	-0.03%
Total Current Liabilities+	8.02B	8.84B	9.56B	10.65B	18.3B	19.08B	21.87B	21.89B	22.26B	23.77B
Accounts Payable	1.56B	1.66B	2.25B	1.89B	2.44B	2.71B	2.95B	3.04B	3.26B	3.6B
Days Payables Outstanding	152.16	123.15	141.03	106.47	100.33	47.57	54.85	56.41	60.54	63
Short-Term Debt	139M	992M	987M	1.7B	3.35B	2.34B	4.95B	4.26B	3.12B	2.05B
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	951M	862M	909M	5.75B	9.35B	11.65B	11.48B	11.99B	12.79B	14.6B
Current Ratio	1.30x	1.55x	1.55x	1.66x	1.60x	1.58x	1.52x	1.25x	1.43x	1.25x
Quick Ratio	1.15x	1.41x	1.43x	1.55x	1.37x	1.47x	1.43x	1.14x	1.31x	1.15x
Cash Conversion Cycle	61.31	72.84	42.8	53.75	183.12	79.4	82.6	97.2	112.7	90.72
Total Non-Current Liabilities+	9.31B	8.52B	12.14B	10.21B	59.94B	61.52B	51.44B	43.81B	43.41B	52.44B
Long-Term Debt	6.55B	5.72B	6.97B	5.65B	43.39B	48.34B	39.6B	35.06B	36.65B	47.6B
Capital Lease Obligations	0	0	0	0	672M	833M	874M	1.26B	1.53B	1.37B
Deferred Tax Liabilities	0	0	0	19M	6.45B	5.41B	4.5B	2.17B	338M	369M
Other Non-Current Liabilities	2.17B	2.26B	4.71B	4.07B	9.01B	6.59B	6.13B	5.05B	4.59B	2.87B
Total Liabilities	17.32B	17.36B	21.7B	20.86B	78.25B	80.6B	73.31B	65.7B	65.67B	76.22B
Total Debt+	6.69B	6.71B	7.96B	7.35B	47.54B	51.67B	45.6B	40.72B	41.46B	51.2B
Net Debt	4.3B	2.47B	2.54B	438M	35.19B	37.13B	31.62B	31.59B	30B	40.85B
Debt / Equity	0.46x	0.41x	0.67x	0.52x	0.92x	1.36x	1.27x	1.31x	1.41x	3.12x
Debt / EBITDA	1.55x	1.21x	1.32x	1.05x	5.81x	3.47x	2.25x	2.08x	2.27x	2.66x
Net Debt / EBITDA	1.00x	0.44x	0.42x	0.06x	4.30x	2.50x	1.56x	1.62x	1.65x	2.12x
Interest Coverage	21.40x	31.01x	26.73x	34.94x	9.82x	3.16x	7.15x	7.53x	7.27x	4.96x
Total Equity+	14.42B	16.35B	11.85B	14.13B	51.7B	37.88B	36.01B	31.12B	29.48B	16.39B
Equity Growth %	-0.04%	0.13%	-0.28%	0.19%	2.66%	-0.27%	-0.05%	-0.14%	-0.05%	-0.44%
Book Value per Share	8.59	9.73	7.17	8.63	30.20	16.78	16.04	14.50	14.19	8.08
Total Shareholders' Equity	14.27B	16.18B	11.74B	14.03B	51.6B	37.82B	35.95B	31.06B	29.43B	16.34B
Common Stock	221M	221M	221M	221M	292M	292M	292M	292M	292M	292M
Retained Earnings	31.61B	33.51B	31.16B	34.06B	34.47B	21.28B	23.82B	25.5B	28.77B	14.91B
Treasury Stock	-16.56B	-16.78B	-19.25B	-19.57B	-25.36B	-26.24B	-31.26B	-38.62B	-43.77B	-43.66B
Accumulated OCI	-2.47B	-2.5B	-2.29B	-2.76B	-1.52B	-1.84B	-1.27B	-1.28B	-1.55B	-1.24B
Minority Interest	158M	170M	106M	96M	100M	60M	60M	57M	55M	53M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	2.1B	3.06B	5.28B	7.07B	8.21B	14.05B	16.21B	13.07B	13.86B	15.19B
Operating CF Margin %	0.13%	0.16%	0.25%	0.31%	0.31%	0.33%	0.35%	0.28%	0.31%	0.31%
Operating CF Growth %	-0.33%	0.45%	0.72%	0.34%	0.16%	0.71%	0.15%	-0.19%	0.06%	0.1%
Net Income	1.63B	4.51B	975M	4.95B	3.46B	-8.99B	7.01B	6.34B	8.04B	-8.93B
Depreciation & Amortization	376M	382M	789M	637M	1.75B	10.38B	10.69B	10.28B	9.76B	9.6B
Stock-Based Compensation	235M	205M	199M	221M	441M	779M	583M	457M	518M	507M
Deferred Taxes	-347M	-204M	453M	45M	-924M	983M	-1.39B	-2.74B	-3.29B	-2.09B
Other Non-Cash Items	945M	-680M	714M	999M	317M	9.92B	578M	955M	744M	15.29B
Working Capital Changes	-735M	-1.15B	2.15B	217M	3.17B	983M	-1.26B	-2.23B	-1.91B	810M
Change in Receivables	-942M	-803M	-431M	-429M	752M	-646M	-1.05B	-663M	-995M	264M
Change in Inventory	97M	-152M	-29M	-216M	463M	2.67B	13M	-69M	-751M	-486M
Change in Payables	-919M	104M	320M	-59M	229M	188M	245M	109M	198M	184M
Cash from Investing+	-1.57B	1.48B	-66M	-2B	-9.91B	-10.86B	-538M	-1.06B	-2.29B	-21.35B
Capital Expenditures	-820M	-1.22B	-1.05B	-951M	-836M	-753M	-973M	-1.12B	-1.21B	-1.25B
CapEx % of Revenue	0.05%	0.06%	0.05%	0.04%	0.03%	0.02%	0.02%	0.02%	0.03%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	-3.62B	-2.65B	-4.08B	-3.54B	7.62B	-1.15B	-16.22B	-16.96B	-9.42B	5.13B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-2.48B	-2.55B	-2.58B	-2.61B	-2.68B	-4.08B	-4.4B	-4.63B	-4.74B	-4.86B
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-9M	15M	-22M	-54M	-53M	542M	641M	984M	27M	-106M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	1.28B	1.84B	4.22B	6.12B	7.37B	13.3B	15.23B	11.95B	12.65B	13.94B
FCF Margin %	0.08%	0.09%	0.2%	0.27%	0.28%	0.31%	0.33%	0.26%	0.28%	0.29%
FCF Growth %	-0.51%	0.43%	1.29%	0.45%	0.21%	0.8%	0.15%	-0.22%	0.06%	0.1%
FCF per Share	0.77	1.10	2.55	3.74	4.31	5.89	6.79	5.57	6.09	6.88
FCF Conversion (FCF/Net Income)	1.35x	0.69x	5.24x	1.44x	2.39x	-1.56x	2.32x	2.07x	1.73x	-1.70x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	10.64%	28.97%	7.14%	37.88%	10.45%	-20.08%	18.93%	18.85%	26.48%	-39.01%
Return on Invested Capital (ROIC)	16.42%	20.69%	23.67%	33.13%	9.52%	4.16%	10.03%	10.67%	10.4%	12.41%
Gross Margin	77.33%	74.61%	72%	71.25%	65.98%	51.04%	57.69%	57.39%	56.34%	56.79%
Net Margin	9.45%	22.94%	4.85%	21.81%	13.15%	-21.16%	15.08%	13.71%	17.83%	-18.53%
Debt / Equity	0.46x	0.41x	0.67x	0.52x	0.92x	1.36x	1.27x	1.31x	1.41x	3.12x
Interest Coverage	21.40x	31.01x	26.73x	34.94x	9.82x	3.16x	7.15x	7.53x	7.27x	4.96x
FCF Conversion	1.35x	0.69x	5.24x	1.44x	2.39x	-1.56x	2.32x	2.07x	1.73x	-1.70x
Revenue Growth	4.29%	17.31%	6.94%	8.59%	15.89%	62.62%	9.1%	-0.49%	-2.5%	7.32%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Eliquis	1.86B	3.34B	4.87B	6.44B	7.93B	9.17B	10.76B	11.79B	12.21B	13.33B
Eliquis Growth	-	79.73%	45.74%	32.14%	23.16%	15.63%	17.39%	9.54%	3.54%	9.23%
Opdivo	942M	3.77B	4.95B	6.74B	7.2B	6.99B	7.52B	8.25B	9.01B	9.3B
Opdivo Growth	-	300.64%	31.11%	36.12%	6.96%	-2.94%	7.59%	9.65%	9.21%	3.27%
Revlimid	-	-	-	-	1.3B	12.11B	12.82B	9.98B	6.1B	5.77B
Revlimid Growth	-	-	-	-	-	831.95%	5.91%	-22.17%	-38.90%	-5.31%
Orencia	1.89B	2.27B	2.48B	2.71B	2.98B	3.16B	3.31B	3.46B	3.6B	3.68B
Orencia Growth	-	20.16%	9.45%	9.32%	9.85%	6.05%	4.72%	4.78%	3.95%	2.25%
Pomalyst/Imnovid	-	-	-	-	322M	3.07B	3.33B	3.5B	3.44B	3.54B
Pomalyst/Imnovid Growth	-	-	-	-	-	853.42%	8.53%	4.95%	-1.60%	3.02%
Yervoy	1.13B	1.05B	1.24B	1.33B	1.49B	1.68B	2.03B	2.13B	2.24B	2.53B
Yervoy Growth	-	-6.48%	18.14%	6.91%	11.95%	12.96%	20.45%	5.18%	5.02%	13.05%
Reblozyl	-	-	-	-	-	274M	551M	717M	1.01B	1.77B
Reblozyl Growth	-	-	-	-	-	-	101.09%	30.13%	40.59%	75.89%
Other Growth Brands	-	-	-	-	-	-	-	-	-	1.6B
Other Growth Brands Growth	-	-	-	-	-	-	-	-	-	-
Sprycel	1.62B	1.82B	2B	2B	2.11B	2.14B	2.12B	2.17B	1.93B	1.29B
Sprycel Growth	-	12.59%	9.92%	-0.25%	5.50%	1.42%	-1.07%	2.27%	-10.85%	-33.37%
Opdualag	-	-	-	-	-	-	-	252M	627M	928M
Opdualag Growth	-	-	-	-	-	-	-	-	148.81%	48.01%
Other Legacy Brands	-	-	-	-	-	-	-	-	-	925M
Other Legacy Brands Growth	-	-	-	-	-	-	-	-	-	-
Abraxane	-	-	-	-	166M	1.25B	1.18B	811M	1B	875M
Abraxane Growth	-	-	-	-	-	651.20%	-5.29%	-31.33%	23.80%	-12.85%
Breyanzi	-	-	-	-	-	-	87M	182M	364M	747M
Breyanzi Growth	-	-	-	-	-	-	-	109.20%	100.00%	105.22%
Camzyos	-	-	-	-	-	-	-	24M	231M	602M
Camzyos Growth	-	-	-	-	-	-	-	-	862.50%	160.61%
Zeposia	-	-	-	-	-	12M	134M	250M	434M	566M
Zeposia Growth	-	-	-	-	-	-	1016.67%	86.57%	73.60%	30.41%
Abecma	-	-	-	-	-	-	164M	388M	472M	406M
Abecma Growth	-	-	-	-	-	-	-	136.59%	21.65%	-13.98%
Sotyktu	-	-	-	-	-	-	-	8M	170M	246M
Sotyktu Growth	-	-	-	-	-	-	-	-	2025.00%	44.71%
Krazati	-	-	-	-	-	-	-	-	-	126M
Krazati Growth	-	-	-	-	-	-	-	-	-	-
Cobenfy	-	-	-	-	-	-	-	-	-	10M
Cobenfy Growth	-	-	-	-	-	-	-	-	-	-
Mature Products And All Other	2.57B	2.14B	2.11B	1.63B	1.67B	1.31B	1.9B	1.75B	-	-
Mature Products And All Other Growth	-	-16.65%	-1.45%	-22.82%	2.70%	-21.45%	44.49%	-7.95%	-	-
Baraclude	1.31B	1.19B	1.05B	744M	555M	447M	-	-	-	-
Baraclude Growth	-	-9.15%	-11.74%	-29.28%	-25.40%	-19.46%	-	-	-	-
Empliciti	3M	150M	231M	247M	357M	381M	-	-	-	-
Empliciti Growth	-	4900.00%	54.00%	6.93%	44.53%	6.72%	-	-	-	-
Reyataz	1.14B	912M	698M	427M	-	-	-	-	-	-
Reyataz Growth	-	-19.93%	-23.46%	-38.83%	-	-	-	-	-	-
Sustiva Franchise	1.25B	1.06B	729M	283M	-	-	-	-	-	-
Sustiva Franchise Growth	-	-14.94%	-31.55%	-61.18%	-	-	-	-	-	-
Hepatitis C Portfolio	1.6B	1.58B	406M	17M	-	-	-	-	-	-
Hepatitis C Portfolio Growth	-	-1.56%	-74.27%	-95.81%	-	-	-	-	-	-
Abilify	746M	128M	-	-	-	-	-	-	-	-
Abilify Growth	-	-82.84%	-	-	-	-	-	-	-	-
Erbitux	501M	-	-	-	-	-	-	-	-	-
Erbitux Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	8.19B	10.72B	11.36B	12.59B	15.34B	26.58B	29.21B	31.83B	31.55B	34.1B
UNITED STATES Growth	-	30.92%	5.95%	10.81%	21.90%	73.23%	9.92%	8.95%	-0.86%	8.08%
Rest Of World	4.14B	3.96B	3.88B	3.73B	4.01B	5.46B	5.63B	-	12.75B	13.2B
Rest Of World Growth	-	-4.30%	-2.19%	-3.71%	7.50%	35.98%	3.21%	-	-	3.51%
Other Region	739M	528M	553M	584M	524M	631M	852M	834M	699M	996M
Other Region Growth	-	-28.55%	4.73%	5.61%	-10.27%	20.42%	35.02%	-2.11%	-16.19%	42.49%
Europe	3.49B	4.21B	4.99B	5.66B	6.27B	9.85B	10.69B	13.5B	-	-
Europe Growth	-	20.74%	18.34%	13.43%	10.75%	57.25%	8.46%	26.29%	-	-

Frequently Asked Questions

Growth & Financials

Bristol-Myers Squibb Company (BMY) reported $48.03B in revenue for fiscal year 2024. This represents a 126% increase from $21.24B in 2011.

Bristol-Myers Squibb Company (BMY) grew revenue by 7.3% over the past year. This is steady growth.

Yes, Bristol-Myers Squibb Company (BMY) is profitable, generating $6.04B in net income for fiscal year 2024 (-18.5% net margin).

Dividend & Returns

Yes, Bristol-Myers Squibb Company (BMY) pays a dividend with a yield of 4.24%. This makes it attractive for income-focused investors.

Bristol-Myers Squibb Company (BMY) has a return on equity (ROE) of -39.0%. Negative ROE indicates the company is unprofitable.

Bristol-Myers Squibb Company (BMY) generated $15.30B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.